Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May:165:105509.
doi: 10.1016/j.neuint.2023.105509. Epub 2023 Mar 11.

Oxidative stress: A target to treat Alzheimer's disease and stroke

Affiliations
Review

Oxidative stress: A target to treat Alzheimer's disease and stroke

Seema Briyal et al. Neurochem Int. 2023 May.

Abstract

Oxidative stress has been established as a well-known pathological condition in several neurovascular diseases. It starts with increased production of highly oxidizing free-radicals (e.g. reactive oxygen species; ROS and reactive nitrogen species; RNS) and becomes too high for the endogenous antioxidant system to neutralize them, which results in a significantly disturbed balance between free-radicals and antioxidants levels and causes cellular damage. A number of studies have evidently shown that oxidative stress plays a critical role in activating multiple cell signaling pathways implicated in both progression as well as initiation of neurological diseases. Therefore, oxidative stress continues to remain a key therapeutic target for neurological diseases. This review discusses the mechanisms involved in reactive oxygen species (ROS) generation in the brain, oxidative stress, and pathogenesis of neurological disorders such as stroke and Alzheimer's disease (AD) and the scope of antioxidant therapies for these disorders.

Keywords: Alzheimer's disease; Antioxidant therapy; Brain disorders; Endothelin B receptors; Endothelins; Oxidative stress; Sovateltide; Stroke.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest A.G. is a Pharmazz, Inc. employee and has issued and pending patents related to the sovateltide studies described in this review. S.B. and A.K.R. declares no competing interests.

Publication types